⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ATAI News
Atai Beckley N.V Common Shares
AtaiBeckley to Participate in Upcoming Needham Healthcare Conferences
globenewswire.com
ATAI
AtaiBeckley’s BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs
globenewswire.com
ATAI
AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst
globenewswire.com
ATAI
Attain Reports Second Consecutive Year of Triple-Digit Enterprise Growth, Scaling B2B Adoption and Advancing the Outcomes Era
globenewswire.com
ATAI
BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation
globenewswire.com
ATAI
BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day
globenewswire.com
ATAI
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
prnewswire.com
GHRS
HELP
DFTX
ATAI
CMPS
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
globenewswire.com
ATAI
AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression
globenewswire.com
ATAI
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
prnewswire.com
GHRS
DFTX
HELP
ATAI
LBRX